David Allsup, MD, Phd

Department Hematology, Hull University Teaching Hospitals NHS Trust, United Kingdom

Poster(s):

• 1226 - Ibrutinib enhances the bias of T-cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia

• 1415 - Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial

• 1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

• 1434 - STATIC TRIAL (Stopping Therapy to Avoid Treatment-resistance In CLL): A randomised phase III trial comparing intermittent with continuous treatment strategies in CLL

• 1437 - Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial

• 1705 - Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group